TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

"CONFLICT OF INTERESTS Nuno A. G. Graça and Jan Voorberg are inventors of a patent application regarding autoantibody‐resistant ADAMTS13 variants. Karen Vanhoorelbeke is a member of the advisory board of Shire‐Takeda and Ablynx‐Sanofi. Agnès Veyradier is a member of the French advisory boards for Sanofi, Takeda, and Roche‐Chugai. Paul Coppo was a member of advisory boards for and received speaker fees from Sanofi, Alexion, Octapharma, and Takeda. Nicolas Béranger and Bérangère S. Joly declare no conflicts of interest."

"This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement number 675746 (PROFILE), from the Netherlands Ministry of Health (PPOC‐18‐022) and from the Innovations Department of Sanquin (Sanquinnovate Research Project SQI/00049 and SQI/00060)."